tbuckley/cabot-search huggingface dataset:
Interventions for chronic palmoplantar pustulosis: abridged Cochrane systematic review and GRADE assessments
Authors: G. Obeid, G. Do, L. Kirby, C. Hughes, E. Sbidian, L. Le Cleach
Journal: British Journal of Dermatology (2020)

Palmoplantar pustulosis (PPP) is a chronic inflammatory disease in which sterile and relapsing pustules appear on the palms and soles.To assess the effects of interventions for chronic PPP to induce and maintain complete remission.We searched for randomized controlled trials (RCTs), including people with PPP or chronic palmoplantar pustular psoriasis, in the Cochrane Skin Specialised Register, CENTRAL, MEDLINE, Embase, LILACS and eight trials registers up to July 2020. Study selection, data extraction and risk-of-bias assessment were carried out independently by two review authors. Certainty of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) method.We included 37 RCTs (1663 participants, 76% women, mean age 50 years). Mean treatment duration was 11 weeks. Topical vitamin D derivative may be more effective than placebo in achieving clearance [risk ratio (RR) 7·83, 95% confidence interval (CI) 1·85-33·12; low-certainty evidence from two trials]. Concerning biological therapies, there was little or no difference between etanercept and placebo in achieving clearance (low-certainty evidence from one trial), ustekinumab is less effective than placebo in reducing severity (low-certainty evidence from one trial), and guselkumab (RR 2·88, 95% CI 1·24-6·69) and secukinumab (RR 1·55, 95% CI 1·02-2·35) are probably better in reducing disease severity (moderate-certainty evidence from two and one trial(s), respectively) but may cause more serious adverse events than placebo.Evidence is lacking for or against major chronic PPP treatments. Risk of bias and imprecision limit our confidence in the results.
Novel Approaches for Omega-3 Fatty Acid Therapeutics: Chronic Versus Acute Administration to Protect Heart, Brain, and Spinal Cord
Authors: Hylde Zirpoli, Chuchun L. Chang, Yvon A. Carpentier, Adina T. Michael-Titus, Vadim S. Ten, Richard J. Deckelbaum
Journal: Annual Review of Nutrition (2020)

This article reviews novel approaches for omega-3 fatty acid (FA) therapeutics and the linked molecular mechanisms in cardiovascular and central nervous system (CNS) diseases. In vitro and in vivo research studies indicate that omega-3 FAs affect synergic mechanisms that include modulation of cell membrane fluidity, regulation of intracellular signaling pathways, and production of bioactive mediators. We compare how chronic and acute treatments with omega-3 FAs differentially trigger pathways of protection in heart, brain, and spinal cord injuries. We also summarize recent omega-3 FA randomized clinical trials and meta-analyses and discuss possible reasons for controversial results, with suggestions on improving the study design for future clinical trials. Acute treatment with omega-3 FAs offers a novel approach for preserving cardiac and neurological functions, and the combinations of acute treatment with chronic administration of omega-3 FAs might represent an additional therapeutic strategy for ameliorating adverse cardiovascular and CNS outcomes.
1305P Health-related quality of life (HRQoL) in a phase III study of first-line brigatinib (BRG) vs crizotinib (CRZ) in NSCLC: Updated results from ALTA-1L
Authors: M.R. Garcia Campelo, Y. Zhu, H.M. Lin, M. Pérol, M. Jahanzeb, S. Popat, P. Zhang, E. Goodman, D.R. Camidge
Journal: Annals of Oncology (2020)
776P Phase II trial of concurrent nivolumab in urothelial bladder cancer with radiation therapy in localized/locally advanced disease for chemotherapy ineligible patients [NUTRA trial]
Authors: U.N. Vaishampayan, L.K. Heilbrun, N. Vaishampayan, C. Li, D. Shi, A. Frazier, J. Maier, B. Dickow, M. Kuettel, G. Chatta, S. George
Journal: Annals of Oncology (2020)
1384P Prognostic factors for survival in patients with metastatic lung adenocarcinoma: Analysis of the SEER database
Authors: B. Campos Balea, J. de Castro Carpeño, B. Massuti, D. Vicente-Baz, D. Pérez Parente, P. Ruiz Gracia, M. Cobo Dols
Journal: Annals of Oncology (2020)
651P Impact of abiraterone acetate plus prednisone (AAP) in patients with castration-sensitive prostate cancer (mCSPC) and visceral metastases: Subgroup analyses of the LATITUDE study
Authors: G. Baciarello, M. Ozguroglu, S.D. Mundle, G. Leitz, U. Richarz, P. Hu, K.N. Chi, K. Fizazi
Journal: Annals of Oncology (2020)
Increased risk of systemic lupus erythematosus in patients with autoimmune haemolytic anaemia: a nationwide population-based cohort study
Authors: Han-You Mo, James Cheng Chung Wei, Xiao-Huan Chen, Hsin-Hua Chen
Journal: Annals of the Rheumatic Diseases (2020)

Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterised by immune inflammation.1 Autoimmune haemolytic anaemia (AIHA) is a pathological state in which antibodies attack red blood cells. AIHA and SLE shared genetic and environmental risk factors and pathophysiological mechanisms.2 AIHA is clearly over-represented in patients with SLE and often occurs before a diagnosis of SLE.3 However, at present, studies on the incidence of SLE in patients with AIHA are scarce. Therefore, we explored the correlation between AIHA and SLE risk in a nationwide, population-based, matched cohort study.

In the 2003–2013 Taiwanese National Health Insurance Database, we identified patients newly diagnosed with AIHA between 2005 and 2012 (online supplemental figure S1). We selected age-matched and sex-matched (1:20) non-AIHA cohort from one million representative populations. From this cohort, we further selected a comparison group via propensity-score matching (PSM, 1:2) for age, sex, comorbidities and possible confounders using the greedy algorithm (online supplemental methods). Ultimately, we identified 713 patients with AIHA and 1416 PSM-matched individuals …
EFFECT OF ADJUVANT RADIATION THERAPY ON LOCAL RESPONSE, DISTANT METASTASIS AND SURVIVAL IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR CARCINOMA
Authors: Soung Won Jeong, Seung Kew Yoon, Jin Dong Kim, Jung Hyun Kwon, Chang Wook Kim, Jin Mo Yang, Sang Wook Choi, Young Sok Lee, Chang Don Lee, Kyu Won Chung, Boo Sung Kim
Journal: Hepatology (2018)
1181P Real-world data on neuroendocrine neoplasms (NENs): Preliminary results of an observational study by the Hellenic Society of Medical Oncology (HeSMO)
Authors: N.G. Tsoukalas, A. Koumarianou, K. Syrigos, S. Angelaki, N. Ziras, M. Demiri, K. Kampoli, A. Ntavatzikos, I. Binas, E. Stergiou, G. Evangelou, M. Georgiadou, A. Papafili, V. Tzouda, A. Karadimou, K.V. Kamposioras, A. Athanasiadis, I. Souglakos, V. Georgoulias, I. Boukovinas
Journal: Annals of Oncology (2020)
222P Rates of cardiac adverse events in older versus younger adults receiving trastuzumab for HER2-positive early breast cancer: Results from 931 patients treated at The Royal Marsden
Authors: N.M.L. Battisti, K.A. Lee, T. Nash, S. Mappouridou, N. Senthivel, K. Asavisanu, M. Obeid, E-S. Tripodaki, V. Angelis, E. Fleming, E.F. Goode, S. John, M.S. Andres, M. Allen, A. Lyon, A. Ring
Journal: Annals of Oncology (2020)
LBA39 3-years follow-up of double-blind randomized phase II comparing concurrent high-dose cisplatin chemo-radiation plus xevinapant or placebo in high-risk patients with locally advanced squamous cell carcinoma of the head and neck
Authors: J. Bourhis, X. Sun, C. Le Tourneau, Y. Pointreau, C. Sire, M-C. Kaminsky-Forrett, A. Coutte, M. Alfonsi, P. Boisselier, L. Martin, J-P. Delord, F. Clatot, J. Biau, F. Rolland, K. Gollmer, S.A. Szyldergemajn, C. Even, Y. Tao
Journal: Annals of Oncology (2020)
Downregulation of MHC Class II in Relapsed AML Cells after Allogeneic Transplantation
Authors: Matt Christopher, Allegra A Petti, Christopher A. Miller, Michael P Rettig, Eric J. Duncavage, Jeffery M. Klco, Nichole M Helton, Michelle O'Laughlin, Catrina Fronick, Robert Fulton, Richard K. Wilson, Lukas D Wartman, John S. Welch, Sharon E Heath, Jacqueline E. Payton, Timothy Aaron Graubert, Daniel C. Link, Matthew J. Walter, Peter Westervelt, Timothy James J Ley, John F DiPersio
Journal: Blood (2017)
817P Response to olaparib monotherapy in relapsed ovarian cancer by HRR gene mutational status and HRD scarring analysis: Results from the randomized phase II CLIO trial
Authors: A. Vanderstichele, L. Loverix, C. De Vogelaere, L. Heyrman, T. Van Gorp, E. Van Nieuwenhuysen, S. Han, S.J.A.R. Olbrecht, P. Berteloot, P. Neven, R. Schepers, P. Busschaert, D. Goossens, D. Lambrechts, I.B. Vergote
Journal: Annals of Oncology (2020)
1415TiP INSIGHT 2: Tepotinib + osimertinib in patients (pts) with EGFR-mutant NSCLC having acquired resistance to first-line osimertinib due to MET amplification (METamp)
Authors: E.F. Smit, E. Felip, N. Karachaliou, B. Ellers-Lenz, Y-L. Wu
Journal: Annals of Oncology (2020)
447P Long term survival with regorafenib: REALITY (real life in Italy) trial - A GISCAD Study
Authors: E. Lai, C. Cremolini, M. Puzzoni, F. Bergamo, G. Zucchelli, M. Libertini, M. Dettori, M. Banzi, A. Boccaccino, S. Cinieri, A. Cavo, G. Piacentini, F. Andreozzi, G.L. Banna, F. Nappo, F. Iachetta, S. Rota, V. Conca, A. Zaniboni, M. Scartozzi
Journal: Annals of Oncology (2020)
Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial
Authors: Alexander P J Vlaar, Sanne de Bruin, Matthias Busch, Sjoerd A M E G Timmermans, Ingeborg E van Zeggeren, Rutger Koning, Liora ter Horst, Esther B Bulle, Frank E H P van Baarle, Marcel C G van de Poll, E Marleen Kemper, Iwan C C van der Horst, Marcus J Schultz, Janneke Horn, Frederique Paulus, Lieuwe D Bos, W Joost Wiersinga, Martin Witzenrath, Simon Rueckinger, Korinna Pilz, Matthijs C Brouwer, Ren-Feng Guo, Leo Heunks, Pieter van Paassen, Niels C Riedemann, Diederik van de Beek
Journal: The Lancet Rheumatology (2020)
1197P Changes in the concentration of EGFR-mutated (EGFR-M+) plasma DNA in the first hours of TKI therapy allow the prediction of tumour response in patients with EGFR-M+ NSCLC
Authors: E.S. Kuligina, F.V. Moiseenko, S.A. Belukhin, T.A. Laidus, A.S. Martianov, A.S. Gabina, A.V. Myslik, N.M. Volkov, K.A. Zagorodnev, M.M. Kholmatov, T.N. Sokolova, M.L. Stepanova, T.N. Shuginova, A.V. Togo, E. Imyanitov
Journal: Annals of Oncology (2020)
Prediction of systemic biomarkers from retinal photographs: development and validation of deep-learning algorithms
Authors: Tyler Hyungtaek Rim, Geunyoung Lee, Youngnam Kim, Yih-Chung Tham, Chan Joo Lee, Su Jung Baik, Young Ah Kim, Marco Yu, Mihir Deshmukh, Byoung Kwon Lee, Sungha Park, Hyeon Chang Kim, Charumathi Sabayanagam, Daniel S W Ting, Ya Xing Wang, Jost B Jonas, Sung Soo Kim, Tien Yin Wong, Ching-Yu Cheng
Journal: The Lancet Digital Health (2020)

The application of deep learning to retinal photographs has yielded promising results in predicting age, sex, blood pressure, and haematological parameters. However, the broader applicability of retinal photograph-based deep learning for predicting other systemic biomarkers and the generalisability of this approach to various populations remains unexplored.With use of 236 257 retinal photographs from seven diverse Asian and European cohorts (two health screening centres in South Korea, the Beijing Eye Study, three cohorts in the Singapore Epidemiology of Eye Diseases study, and the UK Biobank), we evaluated the capacities of 47 deep-learning algorithms to predict 47 systemic biomarkers as outcome variables, including demographic factors (age and sex); body composition measurements; blood pressure; haematological parameters; lipid profiles; biochemical measures; biomarkers related to liver function, thyroid function, kidney function, and inflammation; and diabetes. The standard neural network architecture of VGG16 was adopted for model development.In addition to previously reported systemic biomarkers, we showed quantification of body composition indices (muscle mass, height, and bodyweight) and creatinine from retinal photographs. Body muscle mass could be predicted with an R2 of 0·52 (95% CI 0·51-0·53) in the internal test set, and of 0·33 (0·30-0·35) in one external test set with muscle mass measurement available. The R2 value for the prediction of height was 0·42 (0·40-0·43), of bodyweight was 0·36 (0·34-0·37), and of creatinine was 0·38 (0·37-0·40) in the internal test set. However, the performances were poorer in external test sets (with the lowest performance in the European cohort), with R2 values ranging between 0·08 and 0·28 for height, 0·04 and 0·19 for bodyweight, and 0·01 and 0·26 for creatinine. Of the 47 systemic biomarkers, 37 could not be predicted well from retinal photographs via deep learning (R2≤0·14 across all external test sets).Our work provides new insights into the potential use of retinal photographs to predict systemic biomarkers, including body composition indices and serum creatinine, using deep learning in populations with a similar ethnic background. Further evaluations are warranted to validate these findings and evaluate the clinical utility of these algorithms.Agency for Science, Technology, and Research and National Medical Research Council, Singapore; Korea Institute for Advancement of Technology.
The axis of the receptor for advanced glycation endproducts in asthma and allergic airway disease
Authors: Timothy N. Perkins, Mason L. Donnell, Tim D. Oury
Journal: Allergy (2020)

Asthma is a generalized term that describes a scope of distinct pathologic phenotypes of variable severity, which share a common complication of reversible airflow obstruction. Asthma is estimated to affect almost 400 million people worldwide, and nearly ten percent of asthmatics have what is considered "severe" disease. The majority of moderate to severe asthmatics present with a "type 2-high" (T2-hi) phenotypic signature, which pathologically is driven by the type 2 cytokines Interleukin-(IL)-4, IL-5, and IL-13. However, "type 2-low" (T2-lo) phenotypic signatures are often associated with more severe, steroid-refractory neutrophilic asthma. A wide range of clinical and experimental studies have found that the receptor for advanced glycation endproducts (RAGE) plays a significant role in the pathogenesis of asthma and allergic airway disease (AAD). Current experimental data indicates that RAGE is a critical mediator of the type 2 inflammatory reactions which drive the development of T2-hi AAD. However, clinical studies demonstrate that increased RAGE ligands and signaling strongly correlate with asthma severity, especially in severe neutrophilic asthma. This review presents an overview of the current understandings of RAGE in asthma pathogenesis, its role as a biomarker of disease, and future implications for mechanistic studies, and potential therapeutic intervention strategies.
562P Target engagement and clinical safety of CB-103, a first-in-class small molecule inhibitor of the NOTCH transcription complex
Authors: A.B. Azaro Pedrazzoli, J.M. Perez Garcia, J. Cortés, E. Lopez Miranda, I. Colombo, E. Garralda, D. Hess, P.G. Nuciforo, A. Vivancos, R. Ferrarotto, O. Schoenborn-Kellenberger, K. Jorga, M. Vigolo, L. Beni, R. Lehal, M. Murone, M. Bauer, P. Pisa, F.D. Vogl, A. Stathis
Journal: Annals of Oncology (2020)
Association of Sleep Electroencephalography-Based Brain Age Index With Dementia
Authors: Elissa Ye, Haoqi Sun, Michael J. Leone, Luis Paixao, Robert J. Thomas, Alice D. Lam, M. Brandon Westover
Journal: JAMA Network Open (2020)

<h3>Importance</h3> Dementia is an increasing cause of disability and loss of independence in the elderly population yet remains largely underdiagnosed. A biomarker for dementia that can identify individuals with or at risk for developing dementia may help close this diagnostic gap. <h3>Objective</h3> To investigate the association between a sleep electroencephalography-based brain age index (BAI), the difference between chronological age and brain age estimated using the sleep electroencephalogram, and dementia. <h3>Design, Setting, and Participants</h3> In this retrospective cross-sectional study of 9834 polysomnograms, BAI was computed among individuals with previously determined dementia, mild cognitive impairment (MCI), or cognitive symptoms but no diagnosis of MCI or dementia, and among healthy individuals without dementia from August 22, 2008, to June 4, 2018. Data were analyzed from November 15, 2018, to June 24, 2020. <h3>Exposure</h3> Dementia, MCI, and dementia-related symptoms, such as cognitive change and memory impairment. <h3>Main Outcomes and Measures</h3> The outcome measures were the trend in BAI when moving from groups ranging from healthy, to symptomatic, to MCI, to dementia and pairwise comparisons of BAI among these groups. <h3>Findings</h3> A total of 5144 sleep studies were included in BAI examinations. Patients in these studies had a median (interquartile range) age of 54 (43-65) years, and 3026 (59%) were men. The patients included 88 with dementia, 44 with MCI, 1075 who were symptomatic, and 2336 without dementia. There was a monotonic increase in mean (SE) BAI from the nondementia group to the dementia group (nondementia: 0.20 [0.42]; symptomatic: 0.58 [0.41]; MCI: 1.65 [1.20]; dementia: 4.18 [1.02];<i>P</i> &lt; .001). <h3>Conclusions and Relevance</h3> These findings suggest that a sleep-state electroencephalography-based BAI shows promise as a biomarker associated with progressive brain processes that ultimately result in dementia.
Autophagy and cardiac diseases: Therapeutic potential of natural products
Authors: Xiaoqian Wu, Zumei Liu, Xi‐Yong Yu, Suowen Xu, Jiandong Luo
Journal: Medicinal Research Reviews (2020)

Abstract The global incidence of cardiac diseases is expected to increase in the coming years, imposing a substantial socioeconomic burden on healthcare systems. Autophagy is a tightly regulated lysosomal degradation mechanism important for cell survival, homeostasis, and function. Accumulating pieces of evidence have indicated a major role of autophagy in the regulation of cardiac homeostasis and function. It is well established that dysregulation of autophagy in cardiomyocytes is involved in cardiac hypertrophy, myocardial infarction, diabetic cardiomyopathy, and heart failure. In this sense, autophagy seems to be an attractive therapeutic target for cardiac diseases. Recently, multiple natural products/phytochemicals, such as resveratrol, berberine, and curcumin have been shown to regulate cardiomyocyte autophagy via different pathways. The autophagy‐modifying capacity of these compounds should be taken into consideration for designing novel therapeutic agents. This review focuses on the role of autophagy in various cardiac diseases and the pharmacological basis and therapeutic potential of reported natural products in cardiac diseases by modifying autophagic processes.
1552P Patterns of venous and arterial thromboembolism in patients with advanced pancreatic cancer treated with palliative first line chemotherapy of gemcitabine/nab-paclitxel or FOLFIRINOX
Authors: E. Schwarzenbacher, F. Moik, F. Posch, L. Horvath, A. Gantschnigg, F. Renneberg, D. Barth, M. Stotz, R. Schaberl-Moser, M. Pichler, C. Ay, H. Stöger, R. Greil, A. Djanani, A. Gerger, K. Schlick, J.M. Riedl
Journal: Annals of Oncology (2020)
1006P PD-L1, tumor mutational burden, and overall survival among patients undergoing surgical treatment for hepatocellular carcinoma prior to systemic therapy
Authors: T. Steiniche, M.A. Marsico, A.B. Siegel, H. Gronbaek, S. Ha, J.Y. Hong, Y-H. Paik, J. Georgsen, H-C.L. Pommergaard, M. Ladekarl, A. Webber, X. Liu, A. Kachurak, K. Skaarup, J. Lee, H.Y. Lim
Journal: Annals of Oncology (2020)
1128P Germline variation in PDCD1 is associated with survival in metastatic melanoma after anti-PD-1 monotherapy
Authors: M. De With, D.P. Hurkmans, E. Oomen-de Hoop, A. Lalouti, S. Bins, S. El Bouazzaoui, R. Debets, J.G. Aerts, R.H.N. Van Schaik, R.H. Mathijssen, A.A.M. Van der Veldt
Journal: Annals of Oncology (2020)
1425MO Effects of elemental diet for gastrointestinal adverse events in patients with esophageal cancer receiving docetaxel/cisplatin/5-fluorouracil (EPOC 2 study: JFMC49-1601-C5): A phase III randomized controlled trial
Authors: H. Takeuchi, Y. Tanaka, Y. Nakashima, E. Otsuji, H. Nagano, H. Matsubara, H. Baba, Y. Emi, E. Oki, T. Ueno, K. Tomizuka, S. Morita, C. Kunisaki, J. Hihara, H. Saeki, Y. Hamai, Y. Maehara, Y. Kitagawa, K. Yoshida
Journal: Annals of Oncology (2020)
1238P Quality of life with adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected stage II–IIIA (N1–N2) EGFR-mutant non-small cell lung cancer: Results from the ADJUVANT (CTONG1104) study
Authors: J. Zeng, W. Mao, Q. Chen, T. Luo
Journal: Annals of Oncology (2020)
A Novel Phthalimide-Derivative, TC11, Induced G2/M Arrest and Apoptosis of High-Risk Myeloma Cells By Interacting with Nucleophosmin1 and α-Tubulin, but Not By Binding to Celeblon
Authors: Misa Nakamura, Daiju Ichikawa, Shuji Aida, Nahoko Hashimoto, Wakana Murota, Ryo Uozaki, Mikio Okayama, Kota Fujimori, Yuko Yonemura, Noriko Tabata, Hiroshi Yanagawa, Maiko Matsushita, Yutaka Hattori
Journal: Blood (2017)
Disparities Across Sexual Orientation in Migraine Among US Adults
Authors: Jason M. Nagata, Kyle T. Ganson, Jennifer Tabler, Aaron J. Blashill, Stuart B. Murray
Journal: JAMA Neurology (2020)

Disparities Across Sexual Orientation in Migraine Among US AdultsMigraine affects 1 in 6 adults and represents the fifth leading cause of emergency department visits in the US. 1 Despite an increasing recognition of disparities in migraine prevalence by race/ethnicity, sex, and socioeconomic status, 1 there is a paucity of research on disparities by sexual orientation.Sexual minority groups (eg, lesbian, gay, bisexual, and other nonheterosexual people) may experience unique discrimination, stigma, and barriers to health care access, thus leading to disparities in physical and mental health. 2,3The objective of this study was to determine the association between sexual orientation and migraine in a nationally representative sample of US adults.Methods | Cross-sectional, nationally representative data of US adults ages 31 to 42 years old from Wave V (calendar years 2016-2018) of the National Longitudinal Study of Adolescent to Adult Health (Add Health) were analyzed from May 2020 to June 2020.The University of North Carolina institutional review board approved all study procedures, and written informed consent was obtained from all participants.Migraine was measured based on self-report in response to the interview question, "Have you ever had five or more headaches that were at least four hours long; one-sided, pulsating, intense, or worsened by activity; and associated with nausea, vomiting, or sensitivity to light or sound?" which was consistent with the International Classification of Headache Disorders, third edition diagnostic criteria for migraine without aura. 4Sexual orientation was categorized into 3 categories: exclusively heterosexual; mostly heterosexual but somewhat attracted to people of one's own sex; or lesbian, gay, or bisexual, as has been previously categorized. 5Logistic regression analysis was conducted using Stata version 15.1 (Stata-Corp) with sexual orientation as the independent variable and migraine as the dependent variable, adjusting for sex, race/ ethnicity, age, education, income, smoking, and alcohol use 1 and incorporating national sample weighting.
1537P Phase I/II study with CXCL12 inhibitor NOX-A12 and pembrolizumab in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer
Authors: N. Halama, A. Williams, M. Suarez-Carmona, J. Schreiber, N. Hohmann, U. Pruefer, J. Krauss, D. Jaeger, A. Froemming, D. Beyer, J.U. Jungnelius, A. Mangasarian
Journal: Annals of Oncology (2020)
370MO FOLAGLI: A phase I study of folinic acid combined with temozolomide and radiotherapy to modulate MGMT gene promoter methylation in newly diagnosed MGMT non-methytated glioblastoma
Authors: J-S. Frenel, P-F. Cartron, C. Gourmelon, L. Campion, M. Aumont, P. Augereau, F. Ducray, D. Loussouarn, L. Lallier, M. Robert, M. Campone
Journal: Annals of Oncology (2020)